Document is current

Article History

Received: 30 October 2023

Accepted: 25 September 2024

First Online: 11 October 2024

Declarations

:

: The 2BMOM study was approved by the Danish Data Protection Agency (VD-2018-253), the Finnish Ethics Committee (HUS/1330/2019), and the Swedish Ethics Committee (Dnr: 2019–04451). Approval from the Danish National Ethics Committee was not required as no biomedical intervention was performed. All women gave informed consent to participate. The participants did not receive any reimbursements.

: EM reports grants from Gilead and the Novo Nordisk Foundation; honorarium paid to her institution from GSK, Gilead and Merck Sharp Dohme, outside the submitted work. IA reports personal fees from Merck Sharp Dohme, Gilead, and Glaxo Smith Kline, and a grant from Gilead, outside the submitted work. ÅM reports personal fees from Gilead and ViiV/ GSK, outside the submitted work. TLK reports personal fees and grants from ViiV/Glaxo Smith Kline, Gilead, CLS Behring, and Baxalta, outside of the submitted work. NW reports honorarium paid to her institution from Merck Sharp Dohme, outside the submitted work. The remaining authors (GP, ISJ, DB, and MS) declare no competing interests.